Silexion Shares Surge 158% on Positive SIL-204 Data and S-1 Approval

Silexion Therapeutics Corp: Company Overview

Silexion Therapeutics Corp (NASDAQ: SLXN) is a clinical-stage biotechnology company focused on RNA interference (RNAi) therapies for KRAS-driven solid tumors. Headquartered in Grand Cayman, Cayman Islands, Silexion develops locally administered siRNA products targeting mutant KRAS oncogenes, initially in pancreatic cancer. The company’s lead candidate, SIL-204, is designed for intratumoral, extended-release delivery of siRNA against G12D and G12V KRAS mutations and follows positive Phase 2 data from its first-generation LODER™ platform.

Corporate Structure and Leadership

Silexion employs an estimated 11–50 professionals with expertise in oncology drug development, targeted delivery, and clinical operations. Key executives include:

• Ilan Hadar, Chairman and Chief Executive Officer, with over 20 years in pharmaceutical and high-tech management roles.
• Raeya Horenshtein Hadar, Executive Vice President of Finance, appointed CFO upon completion of the business combination, whose experience encompasses corporate finance, FP&A, and public offerings in biotechnology.
• A multidisciplinary board and clinical team with backgrounds in CRO management, regulatory affairs, and GMP quality oversight support ongoing trials and regulatory interactions.

RNAi Therapeutics by Madison Agardi

Recent Developments and News

On May 29, 2025, Silexion reported preclinical results indicating that SIL-204 inhibited proliferation across KRAS G12D-mutant cell lines in pancreatic, colorectal (GP2D), and non-small-cell lung (A427) cancers in a dose-dependent manner, achieving up to 90% inhibition in colorectal models.
Regulatory filings in early September 2025 included:

• September 4, 2025: SEC notice of effectiveness for its Form S-1 registration statement, permitting capital raises under the Securities Act.
• September 5, 2025: S-1 filing outlining intended use of proceeds for research and development (R&D) and execution of Phase 2/3 clinical trials.
• September 11, 2025: Form 8-K current report detailing corporate updates and governance disclosures.
  On September 11, 2025, SLXN shares closed at USD 11.58, reflecting a percentage increase of 158.19% on a volume of 3.67 million shares traded, according to the broader market data.

Financial and Strategic Analysis

Silexion’s trailing twelve-month indicators highlight early-stage biotechnology characteristics:

• Ticker: SLXN (NASDAQ)
• Market Capitalization (intraday): USD 3.28 million
• 52-Week Range: USD 3.11–63.45
• Volume (average): 76,184
• EPS (TTM): –30.78
• Net Income (TTM): –USD 16.44 million
• Cash (most recent quarter): USD 1.19 million
  The company currently generates minimal revenue, prioritizing R&D expenditures. Its strategic road map focuses on initiating a Phase 2/3 trial of SIL-204 in locally advanced pancreatic cancer with KRAS G12D/V mutations, utilizing its RNAi-PLG microparticle platform to address medical needs in KRAS-driven malignancies.

Market Position and Industry Context

KRAS mutations are implicated in approximately 90% of pancreatic cancers, 45% of colorectal cancers, and 35% of non-small-cell lung cancers, creating annual global treatment markets exceeding USD 30 billion. Traditional small-molecule and antibody therapies face limitations in directly targeting KRAS; Silexion’s RNAi strategy aims to silence oncogenic mRNA within solid tumors. Successful development of SIL-204 could position Silexion as an innovator in KRAS-targeted RNAi therapeutics and facilitate expansion into other high-need indications.

tl;dr

On September 11, 2025, SLXN shares increased by 158.19% to USD 11.58 following the filings of its S-1 effectiveness notice (September 4) and Form 8-K corporate updates (September 11). Preclinical data released on May 29, 2025, demonstrated inhibitory effects of SIL-204 on KRAS G12D-mutant pancreatic, colorectal, and lung cancer cell lines. The company is preparing for a Phase 2/3 trial in locally advanced pancreatic cancer and is positioned to pursue additional KRAS-driven indications, contingent on forthcoming clinical developments and capital acquisition.